Erste Group Bank Issues Positive Forecast for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Investment analysts at Erste Group Bank boosted their FY2026 EPS estimates for Vertex Pharmaceuticals in a research note issued to investors on Monday, July 27th. Erste Group Bank analyst H. Engel now anticipates that the pharmaceutical company will earn $16.95 per share for the year, up from their prior estimate of $16.93. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $17.01 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The business had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. During the same period in the prior year, the company posted $4.06 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis.

VRTX has been the topic of several other reports. Sanford C. Bernstein dropped their price objective on Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Truist Financial increased their target price on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Canaccord Genuity Group dropped their price target on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Barclays boosted their price target on shares of Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada upped their price objective on shares of Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Twenty-two research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $559.61.

Vertex Pharmaceuticals Trading Up 2.4%

NASDAQ VRTX opened at $490.39 on Wednesday. The stock has a market capitalization of $124.46 billion, a price-to-earnings ratio of 29.09, a PEG ratio of 2.16 and a beta of 0.29. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $533.67. The stock has a 50-day moving average of $467.74 and a 200 day moving average of $459.99.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Community Financial Services Group LLC purchased a new position in Vertex Pharmaceuticals in the second quarter valued at $26,000. Motiv8 Investments LLC purchased a new position in Vertex Pharmaceuticals in the fourth quarter valued at approximately $26,000. Elevation Wealth Partners LLC raised its holdings in Vertex Pharmaceuticals by 103.7% during the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 28 shares in the last quarter. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $28,000. Finally, Eagle Bay Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the sale, the executive vice president owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares of the company’s stock, valued at $2,086,446.52. This represents a 6.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 18,874 shares of company stock worth $8,707,966 in the last quarter. 0.20% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.